PMID- 26554790
OWN - NLM
STAT- MEDLINE
DCOM- 20160218
LR  - 20240325
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 44
DP  - 2015 Nov
TI  - Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is 
      Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes.
PG  - e1908
LID - 10.1097/MD.0000000000001908 [doi]
LID - e1908
AB  - Neurofilament (NF), one of the major axonal cytoskeletal proteins, plays a 
      critical role in degenerative diseases in both the central and the peripheral 
      nervous systems. The aim of this study is to explore the relationship between 
      serum phosphorylated neurofilament-heavy chain (pNF-H) and diabetic peripheral 
      neuropathy (DPN) in patients with type 2 diabetes.Serum pNF-H concentrations were 
      measured by ELISA in hospitalized patients with and without DPN (n = 118). DPN 
      was assessed by clinical symptoms, signs, and electromyography.Compared with the 
      non-DPN group (311.98 [189.59-634.12] pg/mL), the confirmed group (605.99 
      [281.17-1332.78] pg/mL) patients had the higher serum pNF-H levels (P = 0.007). 
      DPN was significantly correlated with C-peptide (r = -0.269), total cholesterol 
      (TC) (r = 0.185), and pNF-H (r = 0.258). Serum pNF-H levels were independently 
      associated with DPN (P = 0.004), even after adjusting for age, sex, duration of 
      diabetes, fasting plasma glucose, glycosylated hemoglobin A1c, TC, C-peptide, 
      urinary albuminto/creatinine ratio, and estimated glomerular filtration rate. 
      Compared with pNF-H quartile 1 (referent), patients in quartile 3 (odds ratio 
      [OR], 3.977; 95% confidence interval [CI], 1.243-12.728; P = 0.021) and quartile 
      4 (OR, 10.488; 95% CI, 3.020-34.429; P = 0.000) had the higher risk of DPN after 
      adjusting for the confounders.Serum pNF-H levels might be associated with the 
      DPN, and the correlationship between serum pNF-H and DPN should be further 
      studied.
FAU - Qiao, Xiaona
AU  - Qiao X
AD  - From the Department of Endocrinology and Metabolism, Huashan Hospital, Fudan 
      University, Shanghai, China.
FAU - Zhang, Shuo
AU  - Zhang S
FAU - Zhao, Weiwei
AU  - Zhao W
FAU - Ye, Hongying
AU  - Ye H
FAU - Yang, Yehong
AU  - Yang Y
FAU - Zhang, Zhaoyun
AU  - Zhang Z
FAU - Miao, Qing
AU  - Miao Q
FAU - Hu, Renming
AU  - Hu R
FAU - Li, Yiming
AU  - Li Y
FAU - Lu, Bin
AU  - Lu B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Diabetic Neuropathies/*blood/etiology
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Intermediate Filaments/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Phosphorylation
MH  - Pilot Projects
MH  - Retrospective Studies
PMC - PMC4915891
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2015/11/12 06:00
MHDA- 2016/02/19 06:00
PMCR- 2015/11/06
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/02/19 06:00 [medline]
PHST- 2015/11/06 00:00 [pmc-release]
AID - 00005792-201511030-00030 [pii]
AID - 10.1097/MD.0000000000001908 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Nov;94(44):e1908. doi: 10.1097/MD.0000000000001908.